Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
02
02
2022
accepted:
05
06
2022
pubmed:
19
7
2022
medline:
14
10
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
This study aimed to comprehensively investigate the clinicopathologic characteristics and therapeutic situations of gallbladder neuroendocrine neoplasms (GB-NENs) in the real world via a multicenter, large-scale cohort study. The study searched for patients in 143 hospitals in China and enrolled 154 patients with GB-NENs diagnosed in 40 hospitals between 2004 and 2021. Clinicopathologic characteristics and therapeutic approaches were analyzed retrospectively. The median age at the initial diagnosis of the patients with GB-NENs was 63 years (range 33-83 years), and 61.7% of the patients were women. Tumor-node-metastasis staging classified 92 patients as stage 3 or above. Based on the 2019 World Health Organization classification, 96 cases (62.3%) were confirmed pathologically as poorly differentiated neuroendocrine carcinomas, 13 cases (8.4%) as well-differentiated neuroendocrine tumors, and 45 cases as mixed neuroendocrine-non-neuroendocrine neoplasms. The liver was the most frequent metastatic site. Immunohistochemistry showed that synaptophysin was most frequently positive (80.4%), followed by chromogranin A (61.7%), and CD56 (58.4%). Computed tomography and magnetic resonance imaging showed more common clear boundaries (25/39 cases) and invasive growth features (27 cases). None of these cases had an accurate diagnosis before surgery, with a misdiagnosis rate of 100%. Surgical resection is the main treatment, and platinum-based chemotherapeutic regimens were preferred as adjuvant therapies for patients with GB-NENs. The available survival data for 74 patients showed an overall survival rate of 59% at 1 year, 33% at 3 years, and 29% at 5 years. No significant difference was found between the patients treated with and those treated without adjuvant chemotherapy. Gallbladder neuroendocrine neoplasms have high malignancy and a poor prognosis. Importantly, this large-scale cohort study significantly improves our understanding of GB-NENs and will benefit the exploration of its mechanism and treatment modes. Further investigation is necessary to explore the management of this disease.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to comprehensively investigate the clinicopathologic characteristics and therapeutic situations of gallbladder neuroendocrine neoplasms (GB-NENs) in the real world via a multicenter, large-scale cohort study.
METHODS
METHODS
The study searched for patients in 143 hospitals in China and enrolled 154 patients with GB-NENs diagnosed in 40 hospitals between 2004 and 2021. Clinicopathologic characteristics and therapeutic approaches were analyzed retrospectively.
RESULTS
RESULTS
The median age at the initial diagnosis of the patients with GB-NENs was 63 years (range 33-83 years), and 61.7% of the patients were women. Tumor-node-metastasis staging classified 92 patients as stage 3 or above. Based on the 2019 World Health Organization classification, 96 cases (62.3%) were confirmed pathologically as poorly differentiated neuroendocrine carcinomas, 13 cases (8.4%) as well-differentiated neuroendocrine tumors, and 45 cases as mixed neuroendocrine-non-neuroendocrine neoplasms. The liver was the most frequent metastatic site. Immunohistochemistry showed that synaptophysin was most frequently positive (80.4%), followed by chromogranin A (61.7%), and CD56 (58.4%). Computed tomography and magnetic resonance imaging showed more common clear boundaries (25/39 cases) and invasive growth features (27 cases). None of these cases had an accurate diagnosis before surgery, with a misdiagnosis rate of 100%. Surgical resection is the main treatment, and platinum-based chemotherapeutic regimens were preferred as adjuvant therapies for patients with GB-NENs. The available survival data for 74 patients showed an overall survival rate of 59% at 1 year, 33% at 3 years, and 29% at 5 years. No significant difference was found between the patients treated with and those treated without adjuvant chemotherapy.
CONCLUSIONS
CONCLUSIONS
Gallbladder neuroendocrine neoplasms have high malignancy and a poor prognosis. Importantly, this large-scale cohort study significantly improves our understanding of GB-NENs and will benefit the exploration of its mechanism and treatment modes. Further investigation is necessary to explore the management of this disease.
Identifiants
pubmed: 35849293
doi: 10.1245/s10434-022-12107-w
pii: 10.1245/s10434-022-12107-w
doi:
Substances chimiques
Chromogranin A
0
Synaptophysin
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
7619-7630Subventions
Organisme : Major Scientific Project of Zhejiang Laboratory
ID : 2020ND8AD01
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
pubmed: 18565894
Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855–63.
pubmed: 25918282
Janson ET, Sorbye H, Welin S, et al. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 2010;49:740–56.
pubmed: 20553100
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59.
pubmed: 12569593
Albores-Saavedra J, Batich K, Hossain S, et al. Carcinoid tumors and small cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the surveillance, epidemiology, and end results program. Ann Diagn Pathol. 2009;13:378–83.
pubmed: 19917473
Chen C, Wang L, Liu X, et al. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8:8218–26.
pubmed: 26339390
pmcid: 4555718
Chu H, Zhang C, Shi Y, et al. Gallbladder neuroendocrine carcinoma: a single center experience. Medicine Baltimore. 2020;99:e21912.
pubmed: 32899024
pmcid: 7478469
Zou YP, Li WM, Liu HR, et al. Primary carcinoid tumor of the gallbladder: a case report and brief review of the literature. World J Surg Oncol. 2010;8:12.
pubmed: 20175936
pmcid: 2834672
Lee SM, Sung CO. Neuroendocrine carcinomas of the gallbladder: a clinicopathologic and immunohistochemical analysis of 34 resected cases. Am J Surg Pathol. 2020;44:1308–21.
pubmed: 32739935
Yan S, Wang Y, Chen X, et al. Clinical analysis of 15 cases of gallbladder neuroendocrine carcinoma and comparison with gallbladder adenocarcinoma using a propensity score-matching. Cancer Manag Res. 2020;12:1437–46.
pubmed: 32161496
pmcid: 7049775
Ghosh J, Chatterjee M, Ganguly S, et al. Outcomes of metastatic neuroendocrine carcinoma of the gallbladder. Ecancermedicalscience. 2021;15:1174.
pubmed: 33680088
pmcid: 7929769
Gogna S, Samson D, Gachabayov M, et al. Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome. Langenbecks Arch Surg. 2022;407:197–206.
Cen D, Liu H, Wan Z, et al. Clinicopathological features and survival for gallbladder NEN: a population-based study. Endocr Connect. 2019;8:1273–81.
pubmed: 31398710
pmcid: 6733363
Byrd D, Carducci M, Compton C, et al. AJCC Cancer Staging Manual. 8th edn. New York: Springer; 2017.
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.
pubmed: 31433515
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.
pubmed: 20827404
pmcid: 2900561
Kim JH, Eun HW, Kim YJ, et al. Pancreatic neuroendocrine tumour (PNET): staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol. 2016;26:1338–47.
pubmed: 26253257
Yun SP, Shin N, Seo HI. Clinical outcomes of small cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. World J Gastroenterol. 2015;21:269–75.
pubmed: 25574101
pmcid: 4284345
Adsay NV, La Rosa S. Neuroendocrine neoplasms of the gallbladder and bile ducts. In: WHO Classification of Tumours Editorial Board (ed) Digestive System Tumours WHO Classification of Tumours. 5th ed. IARC, Lyon, 2019, pp 292–4.
Maitra A, Tascilar M, Hruban RH, et al. Small cell carcinoma of the gallbladder: a clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol. 2001;25:595–601.
pubmed: 11342770
Dasari A, Mehta K, Byers LA, et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018;124:807–15.
pubmed: 29211313
Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT. AJR Am J Roentgenol. 2018;211:267–77.
pubmed: 29975116
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
pubmed: 28448665
pmcid: 5824320
Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1–18):vii.
Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:15–31.
pubmed: 17382263
Kim SH, Kim SH, Kim MA, et al. CT differentiation of poorly differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas. Eur Radiol. 2015;25:1946–57.
pubmed: 25899412
Baekdal J, Krogh J, Klose M, et al. Limited diagnostic utility of chromogranin a measurements in workup of neuroendocrine tumors. Diagnostics Basel. 2020;10:881.
pmcid: 7693015
Modlin IM, Kidd M, Falconi M, et al. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol. 2021;32:1425–33.
pubmed: 34390828
Modlin IM, Kidd M, Oberg K, et al. Early identification of residual disease after neuroendocrine tumor resection using a liquid biopsy multigenomic mRNA signature (NETest). Ann Surg Oncol. 2021;28:7506–17.
pubmed: 34008138
Cabibi D, Bellavia S, Giannone AG, et al. TTF-1/p63-positive poorly differentiated NSCLC: a histogenetic hypothesis from the basal reserve cell of the terminal respiratory unit. Diagnostics Basel. 2020;10:25.
Hwang HJ, Nam SK, Park H, et al. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer. J Pathol Transl Med. 2020;54:378–86.
pubmed: 32601264
pmcid: 7483024
Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–51.
pubmed: 15887161
Lamarca A, Frizziero M, Barriuso J, et al. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clin Transl Oncol. 2019;21:950–3.
pubmed: 30506132
Chen X, Wu X, Wu H, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. 2020;8:e001240.
pubmed: 33172881
pmcid: 7656907
Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746.
pubmed: 29624208
Liang X, Yan Y, Wang L, et al. First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncol Lett. 2015;9:987–93.
pubmed: 25621076
Eltawil KM, Gustafsson BI, Kidd M, et al. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44:687–95.
pubmed: 20375728
Adachi T, Haraguchi M, Irie J, et al. Gallbladder small cell carcinoma: a case report and literature review. Surg Case Rep. 2016;2:71.
pubmed: 27457076
pmcid: 4960082
Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–94.
pubmed: 26731334
Zhang J, Kulkarni HR, Singh A, et al. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60:377–85.
pubmed: 30115686
Sorbye H, Kong G, Grozinsky-Glasberg S. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2020;27:R67-77.
pubmed: 31846429
Shintaku M, Kataoka K, Kawabata K. Mixed adenoneuroendocrine carcinoma of the gallbladder with squamous cell carcinomatous and osteosarcomatous differentiation: report of a case. Pathol Int. 2013;63:113–9.
pubmed: 23464969
Wen LJ, Chen JH, Xu HJ, et al. The clinical profiles, management, and prognostic factors of biliary mixed neuroendocrine nonneuroendocrine neoplasms: a systematic review of the literature. Medicine Baltimore. 2020;99:e23271.
pubmed: 33327249
pmcid: 7738038
Maru DM, Khurana H, Rashid A, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.
pubmed: 18670347
Sciarra A, Missiaglia E, Trimech M, et al. Gallbladder mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) arising in intracholecystic papillary neoplasm: clinicopathologic and molecular analysis of a case and review of the literature. Endocr Pathol. 2020;31:84–93.
pubmed: 31981075
Sakaki M, Hirokawa M, Sano T, et al. Gallbladder adenocarcinoma with florid neuroendocrine cell nests and extensive paneth cell metaplasia. Endocr Pathol. 2000;11:365–71.
pubmed: 12114761
Yang M, Ke NW, Zhang Y, et al. Survival analyses for patients with surgically resected pancreatic neuroendocrine tumors by World Health Organization 2010 grading classifications and American Joint Committee on Cancer 2010 staging systems. Medicine Baltimore. 2015;94:e2156.
pubmed: 26632896
pmcid: 4674199
Holmager P, Willemoe GL, Nielsen K, et al. Neuroendocrine neoplasms of the appendix: characterization of 335 patients referred to the Copenhagen NET Center of Excellence. Eur J Surg Oncol. 2021;47:1357–63.
pubmed: 33589240
Liu F, Li Y, Ying D, et al. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. Signal Transduct Target Ther. 2021;6:55.
pubmed: 33563892
pmcid: 7873252
Hu Q, Zhang B, Chen R, et al. ZFHX3 is indispensable for Erbeta to inhibit cell proliferation via MYC downregulation in prostate cancer cells. Oncogenesis. 2019;8:28.
pubmed: 30979864
pmcid: 6461672